Message : Required fields CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021 Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM) initiative - $5.5 million for ramping manufacturing of Revogene ® SARS-CoV-2 Assay ® Campy assay Launched first Air-Dryable sample specific Master Mix for Blood